An open label study to evaluate the effect of first line treatment with Tarceva [erlotinib] in combination with gemcitabine on overall survival and disease progression in patients with locally advanced, unresectable or metastatic pancreatic cancer.

Status: Discontinued

Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2016

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs Erlotinib (Primary) ; Gemcitabine
Indications Pancreatic cancer
Focus Therapeutic Use
Sponsors Roche

Most Recent Events

17 Jun 2008 Status changed from recruiting to discontinued as reported by ClinicalTrials.gov.
09 Apr 2008 New trial record.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com

Welcome to AdisInsight